Related Experiment Video

Updated: May 25, 2026

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies
07:06

Preparation of Washed Human Platelets for Quantitative Metabolic Flux Studies

Published on: January 10, 2025

Variability in the response to antiplatelet treatment in diabetes mellitus

Giovanni Davì1, Natale Vazzana, Simona Sestili

  • 1Internal Medicine and Center of Excellence on Aging, "G. D'Annunzio" University of Chieti, Italy. gdavi@unich.it

Prostaglandins & Other Lipid Mediators
|February 15, 2012
PubMed

Insights

Diabetic patients often experience treatment failure with antiplatelet drugs like aspirin due to interindividual variability. This review explores pharmacokinetic and pharmacodynamic factors affecting aspirin efficacy and safety in diabetes mellitus.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Endocrinology

Background:

  • Atherothrombosis is a primary cause of mortality in diabetes mellitus patients.
  • Platelet activation significantly contributes to the prothrombotic state in diabetes.
  • Existing research on antiplatelet therapy for diabetic cardiovascular prevention shows limited evidence for low-dose aspirin effectiveness.

Purpose of the Study:

  • To review the determinants of interindividual variability in response to antiplatelet agents in patients with diabetes mellitus.
  • To emphasize the pharmacokinetic and pharmacodynamic mechanisms influencing antiplatelet drug efficacy and safety in this population.

Main Methods:

  • Literature review of studies investigating antiplatelet therapy in diabetic patients.
  • Analysis of disease-specific factors contributing to aspirin treatment failure.
  • Examination of pharmacokinetic and pharmacodynamic mechanisms of antiplatelet drug action.

Main Results:

  • Several diabetes-specific factors influence interindividual variability in response to antiplatelet therapy.
  • Pharmacokinetic and pharmacodynamic mechanisms are key determinants of aspirin efficacy and safety.
  • Limited evidence supports the effectiveness of low-dose aspirin in diabetic cardiovascular prevention.

Conclusions:

  • Understanding interindividual variability in antiplatelet response is crucial for optimizing therapy in diabetic patients.
  • Further research is needed to elucidate the specific pharmacokinetic and pharmacodynamic factors affecting antiplatelet drug outcomes in diabetes.
  • Personalized antiplatelet strategies may be necessary to improve cardiovascular outcomes in patients with diabetes mellitus.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...